Bevacizumab in Glaucoma: Where do We Stand?

Khanna, Anjani

doi:10.5005/jp-journals-10008-1110

Cited by 1 publication

(1 citation statement)

References 32 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intravitreal injection of other anti-VEGF agents such as bevacizumab has been found to play a role in iris neo vessel regression and IOP control in cases of neovascular glaucoma (NVG), and potentially affects the success rate of trabeculectomy with MMC administration. However, this effect lasts for a limited time, and re-injection was recommended to maintain this effect [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy

Yaakub

Rahman

Jaafar

et al. 2023

IJMS

View full text Add to dashboard Cite

Post-surgical scarring is a known cause of trabeculectomy failure. The aim of this study was to investigate the effectiveness of ranibizumab as an adjuvant anti-scarring agent in experimental trabeculectomy. Forty New Zealand white rabbits were randomised into four eye treatment groups: groups A (control), B (ranibizumab 0.5 mg/mL), C (mitomycin C [MMC] 0.4 mg/mL), and D (ranibizumab 0.5 mg/mL and MMC 0.4 mg/mL). Modified trabeculectomy was performed. Clinical parameters were assessed on post-operative days 1, 2, 3, 7, 14, and 21. Twenty rabbits were euthanised on day 7, and the other twenty were euthanised on day 21. Eye tissue samples were obtained from the rabbits and stained with haematoxylin and eosin (H&E). All treatment groups showed a significant difference in IOP reduction compared with group A (p < 0.05). Groups C and D showed a significant difference in bleb status on days 7 (p = 0.001) and 21 (p = 0.002) relative to group A. H&E staining showed significantly low fibrotic activity (p < 0.001) in group C on both days and inflammatory cell grade in group B on day 7 (p < 0.001). The grade for new vessel formation was significantly low in groups B and D on day 7 (p < 0.001) and in group D on day 21 (p = 0.007). Ranibizumab plays a role in reducing scarring, and a single application of the ranibizumab–MMC combination showed a moderate wound-modulating effect in the early post-operative phase.

show abstract

Section: Discussionmentioning

confidence: 99%